Monday, February 28, 2022: Life Sciences

Drugmaker Viatris Inc., formerly known as Mylan NV, will pay $264 million to settle a class-action lawsuit alleging it engaged in anticompetitive behavior to delay generic competition to its EpiPen allergy treatment. The litigation has been ongoing for years,...